Biomarin Pharmaceutical Inc. - Registered Shares

NASDAQ:BMRN   3:59:54 PM EDT
100.98
+3.86 (+3.97%)
Products

BioMarin Announces Advancements In FDA Review Of Roctavian (Valoctocogene Roxaparvovec) For Adults With Severe Hemophilia A

Published: 11/23/2022 14:03 GMT
Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) - Biomarin Announces Advancements in FDA Review of Roctavian™ (valoctocogene Roxaparvovec) for Adults With Severe Hemophilia A.
Biomarin Pharmaceutical Inc - Remains on Track to Host Scheduled Manufacturing Inspections by FDA in Coming Weeks.
Biomarin Pharmaceutical FDA No Longer Plans to Hold an Advisory Committee Meeting, As Previously Planned, to Discuss Biologics License Application.